4 ms·

Moderna Phase 1 results show coronavirus vaccine safe, induces immune response

44 points by stx 6y ago

nknealk 6y ago
Link to the actual NEJM publication for those interested: https://www.nejm.org/doi/full/10.1056/NEJMoa2022483 https://www.nejm.org/doi/full/10.1056/NEJMoa2022483 Some interesting snippets: “one participant in the 25-μg group was withdrawn because of an unsolicited adverse event, transient urticaria, judged to be related to the first vaccination.” Also probably more important than antibodies: “The 25-μg and 100-μg doses elicited CD4 T-cell responses (Figs. S9 and S10) that on stimulation by S-specific peptide pools were strongly biased toward expression of Th1 cytokines (tumor necrosis factor α > interleukin 2 > interferon γ), with minimal type 2 helper T-cell (Th2) cytokine expression (interleukin 4 and interleukin 13). CD8 T-cell responses to S-2P were detected at low levels after the second vaccination in the 100-μg dose group (Fig. S11).”
- epoll 6y ago
  Could you explain the snippet in plain English? Thanks!
  - DoingIsLearning 6y ago
    They stopped the treatment for one person in the experiment group treated with 25 microgram dosage, because they showed a side-effect of itchy skin. There is a bunch of white blood cells that produce things called cytokines which act as messengers on immune response. When you want to kill a pathogen you produce Th1. When you produce too much of it you risk killing your own tissue to cancel that you produce Th2. A balance between Th1 and Th2 is needed so that you don't kill yourself while trying to kill pathogens. P.S.: not an immunologist.
- Bluestein 6y ago
  > unsolicited adverse event ... ... as opposed to a solicited adversity? :)
vmurthy 6y ago
Oxford is set to publish its results in The Lancet on Jul 20[0]. Would be interesting to see the differences and how these two compare (there must be something based on which we could say one is better than the other?) [0] https://www.nbcnews.com/health/health-news/covid-19-vaccine-early-oxford-trial-data-be-published-next-n1233919 https://www.nbcnews.com/health/health-news/covid-19-vaccine-...

44 points by stx 6y ago

Link to the actual NEJM publication for those interested: https://www.nejm.org/doi/full/10.1056/NEJMoa2022483 https://www.nejm.org/doi/full/10.1056/NEJMoa2022483 Some interesting snippets: “one participant in the 25-μg group was withdrawn because of an unsolicited adverse event, transient urticaria, judged to be related to the first vaccination.” Also probably more important than antibodies: “The 25-μg and 100-μg doses elicited CD4 T-cell responses (Figs. S9 and S10) that on stimulation by S-specific peptide pools were strongly biased toward expression of Th1 cytokines (tumor necrosis factor α > interleukin 2 > interferon γ), with minimal type 2 helper T-cell (Th2) cytokine expression (interleukin 4 and interleukin 13). CD8 T-cell responses to S-2P were detected at low levels after the second vaccination in the 100-μg dose group (Fig. S11).”

epoll 6y ago
Could you explain the snippet in plain English? Thanks!
- DoingIsLearning 6y ago
  They stopped the treatment for one person in the experiment group treated with 25 microgram dosage, because they showed a side-effect of itchy skin. There is a bunch of white blood cells that produce things called cytokines which act as messengers on immune response. When you want to kill a pathogen you produce Th1. When you produce too much of it you risk killing your own tissue to cancel that you produce Th2. A balance between Th1 and Th2 is needed so that you don't kill yourself while trying to kill pathogens. P.S.: not an immunologist.
Bluestein 6y ago
> unsolicited adverse event ... ... as opposed to a solicited adversity? :)

vmurthy 6y ago

Oxford is set to publish its results in The Lancet on Jul 20[0]. Would be interesting to see the differences and how these two compare (there must be something based on which we could say one is better than the other?) [0] https://www.nbcnews.com/health/health-news/covid-19-vaccine-early-oxford-trial-data-be-published-next-n1233919 https://www.nbcnews.com/health/health-news/covid-19-vaccine-...